https://www.targovax.com/en/targovax-asa-announces-proposed-new-chairman-of-the-board/


Chairman of the Nomination Committee, Mr. Ludvik Sandnes says: “We are very pleased to propose Mr. Damian Marron as new Chairman of the Board. At this stage of the development of Targovax, it is important to propose a proven Chairman with extensive industry experience to achieve our commercial and scientific goals. He has a very strong track record of value creation through public and VC financing, M&A, strategic and portfolio planning and company development. His wide network of contacts globally from big pharma through to biotech companies and with investors, banks and analysts will prove invaluable. This will enable him to bring considerable experience and solutions to Targovax as we continue to develop our clinical pipeline of oncolytic viruses to target hard-to-treat solid tumors for patients.”




Om Damian Marron

Non-Executive Director at Bone Therapeutics, a clinical stage, regenerative medicine company listed on Euronext; Non-Executive director at Resolys Bio, a private, late pre-clinical US startup and Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory boutique. Recently Chair of Board, PepGen Ltd, a cutting-edge platform peptide drug development and delivery company, spun out from the University of Oxford

Accomplished CEO and Non-Executive director with successful track record of leadership in public and private biotechnology companies, notably in the niche/orphan disease marketplace.

CEO of Agalimmune Ltd, a private UK-based company with an innovative, anti-cancer immunotherapy platform, Sept 2015 to March 2017. Negotiated acquisition of Agalimmune by BioLine Rx, a Nasdaq listed, Israeli clinical-stage biopharmaceutical company focused on oncology and immunology.

CEO of TxCell, a T-cell immunotherapy company, from Sept 2013 to April 2015. Led successful IPO in April 2014 on Paris Euronext exchange and raised approx. €20M during tenure.

CEO of Cytheris SA, 2012-2013, a clinical stage biotechnology company focused on immunology through the development of IL-7 based therapeutics in orphan and niche indications.

CEO of Trophos SA from 2008 to 2012. Positioned Trophos to be subsequently acquired by Roche for up to €700M. During tenure attracted EUR 34 million in funding enabling Trophos to complete its clinical programs with success in Spinal Muscular Atrophy.

Prior to Trophos, Executive Vice President Corporate Development at NicOx SA for six years. Responsible for the establishment of major collaborations with Merck and Co. Inc. and Pfizer Inc. and played key role in financing rounds for NicOx, raising in excess of EUR 175 million.

Previously, held various business development and R&D roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo.


http://www.bonetherapeutics.com/en/board-of-directors

...As Chief Executive Officer of Trophos, France, he helped raise EUR 34 million in financing and positioned the company for a subsequent acquisition by Roche for EUR 700 million...


https://treehillpartners.com/leadership/damian-marron/

http://resolysbio.com/management/


Lykke til!